Literature DB >> 31383261

When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.

Thea Brennan-Krohn1, James E Kirby2.   

Abstract

Antibacterial combinations have long been used to accomplish a variety of therapeutic goals, including prevention of resistance and enhanced antimicrobial activity. In vitro synergy testing methods, including the checkerboard array, the time-kill study, diffusion assays, and pharmacokinetic/pharmacodynamic models, are used commonly in the research setting, but are not routinely performed in the clinical microbiology laboratory because of test complexity and uncertainty about their predictive value for patient outcomes. Optimized synergy testing techniques and better data on the relationship between in vitro results and clinical outcomes are needed to guide the rational use of antimicrobial combinations in the multidrug resistance era.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Antimicrobial susceptibility testing; Antimicrobial synergy; Checkerboard array; Hollow fiber infection model; Synergy testing; Time-kill assay

Mesh:

Substances:

Year:  2019        PMID: 31383261      PMCID: PMC6686866          DOI: 10.1016/j.cll.2019.04.002

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  64 in total

1.  Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Authors:  Arnold Louie; Weiguo Liu; Michael VanGuilder; Michael N Neely; Alan Schumitzky; Roger Jelliffe; Steven Fikes; Stephanie Kurhanewicz; Nichole Robbins; David Brown; Dodge Baluya; George L Drusano
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

2.  Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp).

Authors:  Alessandra Oliva; L Scorzolini; D Castaldi; F Gizzi; M De Angelis; M Storto; A D'Abramo; F Aloj; M T Mascellino; C M Mastroianni; V Vullo
Journal:  J Infect       Date:  2016-10-25       Impact factor: 6.072

Review 3.  Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Authors:  Phillip J Bergen; Zackery P Bulman; Sarith Saju; Juergen B Bulitta; Cornelia Landersdorfer; Alan Forrest; Jian Li; Roger L Nation; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2015-01       Impact factor: 4.705

Review 4.  Trimethoprim-sulfamethoxazole: in vitro microbiological aspects.

Authors:  S R Bushby
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

Review 5.  Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis.

Authors:  M McGrath; N C Gey van Pittius; P D van Helden; R M Warren; D F Warner
Journal:  J Antimicrob Chemother       Date:  2013-09-26       Impact factor: 5.790

Review 6.  Aminoglycoside resistance in enterococci.

Authors:  J W Chow
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

7.  Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.

Authors:  Madhuri M Sopirala; Julie E Mangino; Wondwossen A Gebreyes; Beth Biller; Tammy Bannerman; Joan-Miquel Balada-Llasat; Preeti Pancholi
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

Review 8.  Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.

Authors:  Cornelia B Landersdorfer; Rajbharan Yadav; Jürgen B Bulitta; Kate E Rogers; Tae Hwan Kim; Beom Soo Shin; John D Boyce; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

10.  Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents.

Authors:  Jillian L Descourouez; Margaret R Jorgenson; Justine E Wergin; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

View more
  5 in total

1.  Hypericum erectum alcoholic extract inhibits Toxoplasma growth and Entamoeba encystation: an exploratory study on the anti-protozoan potential.

Authors:  Noriko Shinjyo; Hideyuki Nakayama; Kanji Ishimaru; Kenji Hikosaka; Fumika Mi-Ichi; Kazumi Norose; Hiroki Yoshida
Journal:  J Nat Med       Date:  2019-11-14       Impact factor: 2.343

Review 2.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

3.  Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli.

Authors:  Luísa V Zacharias; Natália C Moreira; Nathália Abichabki; Fernando Bellissimo-Rodrigues; Fernanda L Moreira; Jhohann R L Benzi; Tânia M C Ogasawara; Joseane C Ferreira; Camila M Ribeiro; Fernando R Pavan; Leonardo R L Pereira; Guilherme T P Brancini; Gilberto Ú L Braga; Antonio W Zuardi; Jaime E C Hallak; José A S Crippa; Vera L Lanchote; Rafael Cantón; Ana Lúcia C Darini; Leonardo N Andrade
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

4.  ICU-Associated Gram-Negative Bloodstream Infection: Risk Factors Affecting the Outcome Following the Emergence of Colistin-Resistant Isolates in a Regional Greek Hospital.

Authors:  Marios Karvouniaris; Garyphallia Poulakou; Konstantinos Tsiakos; Maria Chatzimichail; Panagiotis Papamichalis; Anna Katsiaflaka; Katerina Oikonomou; Antonios Katsioulis; Eleni Palli; Apostolos Komnos
Journal:  Antibiotics (Basel)       Date:  2022-03-17

Review 5.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.